Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136384

Published: 2020

Journal Articles

CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL

Leslie Popplewell, MD, Xiuli Wang, PhD, Suzette Blanchard, PhD, Jamie Wagner, BS, Araceli Naranjo, BS, Arencibia Adria, BS, Jinny Paul, PhD, Laura Lim, Wen-Chung Chang, PhD, Elizabeth E Budde, MD PhD, Sandra Thomas, PhD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 610.

https://doi.org/10.1182/blood-2018-99-119650

Published: 2018

Journal Articles

The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

Xiuli Wang, PhD, Christian Huynh, Ryan Urak, Miriam Walter, Lihong Weng, MD, Laura Lim, Vibhuti Vyas, Brenda Aguilar, Alfonso Brito, Aniee Sarkissian, Achini Bandara, PhD, Elizabeth E Budde, MD PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Christine Brown, PhD, Stephen J Forman

Blood (2018) 132 (Supplement 1): 965.

https://doi.org/10.1182/blood-2018-99-119335

Published: 2018

Journal Articles

Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation

Alex Iukuridze, Meisi Xiao, MPH, Lee Brandyn, Jennifer Berano Teh, Kristen Mascarenhas, Sandra Xu, Nicholas Rosen, Jeannine S McCune, PharmD, Jasmine M. Zain, MD, Robert W. Chen, MD, Leslie Popplewell, MD, Jessica Scott, PhD, Thomas Slavin, MD, Lee Jones, PhD, Stephen J Forman, Ryotaro Nakamura, MD, F. Lennie Wong, PhD, Saro H. Armenian, DO,MPH

Blood (2018) 132 (Supplement 1): 620.

https://doi.org/10.1182/blood-2018-99-113689

Published: 2018

Journal Articles

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Lu Chen, PhD, Alex F. Herrera, MD, Matthew Mei, MD, Katrina McBride, Rosie Abary, Tanya Siddiqi, MD, Leslie Popplewell, MD, Stephen J Forman, Steven T Rosen, Larry W Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2018-99-110403

Published: 2018

Journal Articles

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Blood (2018) 132 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2018-99-110334

Published: 2018

Journal Articles

Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Alex Francisco Herrera, MD, Saro H. Armenian, DO,MPH, Matthew Mei, MD, Leslie Popplewell**, MD, Abbey Fueger, Imran Qasim, Tracy Stiller, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD

Blood (2017) 130 (Supplement 1): 738.

https://doi.org/10.1182/blood.V130.Suppl_1.738.738

Published: 2017

Journal Articles

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Leslie Popplewell**, MD, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, MDBS, Tanya Siddiqi, MD, Nicole Tsai, Fay Zuo, Rosie Abary, Ji-lian Cai, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD, Leona Holmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4515.

https://doi.org/10.1182/blood.V130.Suppl_1.4515.4515

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

Journal Articles

Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation

Blood (2016) 128 (22): 830.

https://doi.org/10.1182/blood.V128.22.830.830

Published: 2016

Journal Articles

New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells

Xiuli Wang, MD PhD, Ryan Urak, MS, Walter Miriam, MS, Laura Lim, BS, Brenda Aguilar, BS, Alfonso Brito, BS, Aniee Sarkissian, BS, Christine Brown, PhD, Sandra H. Thomas, PhD, Leslie Popplewell, MD, Lihua E. Budde, MD PhD, Stephen J. Forman, MD

Blood (2016) 128 (22): 2161.

https://doi.org/10.1182/blood.V128.22.2161.2161

Published: 2016

Journal Articles

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Leslie Popplewell, MD, Xiuli Wang, PhD, Araceli Naranjo, BS, Suzette Blanchard, PhD, Jamie Wagner, BS, ChingLam Wong, BS, Ryan Urak, MS, Wen-Chung Chang, MS, Samer K Khaled, MD, Tanya Siddiqi, MD, Elizabeth E. Budde, MD PhD, Jingying Xu, PhD, Brenda Chang, BS, Sandra H. Thomas, PhD, Stanley R. Riddell, MD, Christine Brown, PhD, Michael C Jensen, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 930.

https://doi.org/10.1182/blood.V126.23.930.930

Published: 2015

Journal Articles

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Tanya Siddiqi, MD, Anna Scuto, PhD, Jan H. Beumer, PharmD, PhD, Joo Y. Song, MD, Paul Frankel, PhD, Chris Ruel, MS, Jacob Cobb, BS, Brian F. Kiesel, BS, Dennis D. Weisenburger, MD, Kevin R. Kelly, MD PhD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, PhD MD, Edward M. Newman, PhD

Blood (2015) 126 (23): 2731.

https://doi.org/10.1182/blood.V126.23.2731.2731

Published: 2015

Journal Articles

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Tanya Siddiqi, MD, Paul Frankel, PhD, Chris Ruel, MS, Robert W Chen, MD, Kevin R. Kelly, MD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, MD PhD, Edward Newman, PhD

Blood (2014) 124 (21): 4483.

https://doi.org/10.1182/blood.V124.21.4483.4483

Published: 2014

Journal Articles

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Andrei R. Shustov, MD, Bertrand Coiffier, MD, PhD, Steven M. Horwitz, MD, Lubomir Sokol, MD, Ph.D, Barbara Pro, MD, Tina Nielsen, MD, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Robin Eisch, RN, Leslie Popplewell, MD, Miles Prince, MD, FRACP, FRCPA, Steven L. Allen, M.D., Richard Piekarz, MD, PhD, Susan E. Bates, MD

Blood (2013) 122 (21): 4385.

https://doi.org/10.1182/blood.V122.21.4385.4385

Published: 2013

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Ryotaro Nakamura, Robert Chen, MD, Joycelynne Palmer, PhD, Karl Gaal, MD, Auayporn Nademanee, MD, Leslie Popplewell, MD, James E. Talmadge, PhD, Stephen Gillies, PhD, David Colcher, PhD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2013) 122 (21): 1808.

https://doi.org/10.1182/blood.V122.21.1808.1808

Published: 2013

Journal Articles

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Michael Wang, M.D., Leslie Popplewell, MD, Robert H. Collins, Jr., MD, Jane N. Winter, MD, Andre Goy, MD, Anna Robeva, MS, Nicoletta Pirotta, Jenna Fan, Judith Klimovsky, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2751.

https://doi.org/10.1182/blood.V120.21.2751.2751

Published: 2012

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

NARROW

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL

The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation

New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only